We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cerevel Therapeutics Holdings Inc (CERE) USD0.0001

Sell:$41.80 Buy:$42.30 Change: $0.17 (0.41%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$41.80
Buy:$42.30
Change: $0.17 (0.41%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$41.80
Buy:$42.30
Change: $0.17 (0.41%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Contact details

Address:
222 Jacobs Street, Suite 200
CAMBRIDGE
02141
United States
Telephone:
+1 (212) 2842300
Website:
https://www.cerevel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CERE
ISIN:
US15678U1280
Market cap:
$7.61 billion
Shares in issue:
181.58 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • N. Coles
    Chairperson of the Board of Directors
  • Ronald Renaud
    President, Chief Executive Officer, Member of the Board
  • Susan Altschuller
    Chief Financial Officer
  • Kenneth Dipietro
    Chief Human Resources Officer
  • Mark Bodenrader
    Senior Vice President - Finance, Chief Accounting Officer
  • John Renger
    Chief Scientific Officer
  • Raymond Sanchez
    Chief Medical Officer
  • Kathleen Tregoning
    Chief Corporate Affairs Officer
  • Scott Akamine
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.